Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First report of successful pregnancies after treatment with alpelisib for PIK3CA-related overgrowth spectrum

6 Jun 2025

Abstract excerpt

Alpelisib is a selective PI3Kα inhibitor approved for treating PIK3CA-related overgrowth spectrum (PROS), a group of rare malformation disorders. Given that PI3Kα is a ubiquitous protein involved in cell proliferation, understanding the long-term impact of alpelisib on fertility is of critical importance. Here, we report the favorable outcomes of three pregnancies in PROS patients after prolonged treatment with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Renal cell carcinoma treatment
Share to Renal Diseases and Glomerulopathies
Share to Vascular Malformations and Hemangiomas

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40481231
DOI: 10.1038/s41431-025-01885-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First report of successful pregnancies after treatment with alpelisib for PIK3CA-related overgrowth spectrumPMID 40481231Read ↗

PIK3CA-Related Overgrowth Spectrum From Diagnosis to Targeted Therapy: A Case of CLOVES Syndrome Treated With AlpelisibSemantic proximity Read ↗

Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib.Semantic proximity Read ↗

Response to Alpelisib in Clinically Distinct Pediatric Patients With PIK3CA -related Disorders.Semantic proximity Read ↗

Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrumSemantic proximity Read ↗

PIK3CA vascular overgrowth syndromes: an update.Semantic proximity Read ↗

Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrum.Semantic proximity Read ↗

Somatic PIK3R1 mutations in the iSH2 domain are accessible to PI3Kα inhibition.Semantic proximity Read ↗

Alpelisib in pediatric PIK3CA- and TIE-2–mutant vascular anomalies: a case series on safety, efficacy, and drug exposureSemantic proximity Read ↗

Updates on Diagnosis and Treatment of PIK3CA-Related Overgrowth Spectrum.Semantic proximity Read ↗

Early diagnosis enabling precision medicine treatment in a young boy with PIK3R1-related overgrowth.Semantic proximity Read ↗

Four-month-old with severe PIK3CA-related overgrowth spectrum disorder successfully treated with alpelisb.Semantic proximity Read ↗

Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.